# Clinical Trials Data EGFR - Document 63

# Prognostic Relevance of Biological Subtype in Breast Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT02063906

"eligibilityCriteria": "Inclusion Criteria:\n\n\* patients who received curative surgery\n\* stage I-III breast cancer\n\* between January 2004 and September 2008\n\* had available immunohistochemistry profiles.\n\nexclusion Criteria:\n\n\* age \\<18 years old\n\* microinvasive carcinoma of breast",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients who received curative surgery for stage I-III breast cancer between January 2004 and September 2008 and had available immunohistochemistry profiles.",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial is specifically for breast cancer. The eligibility criteria mention nothing about EGFR mutations, which are more commonly associated with lung cancer. Therefore, having an EGFR mutation wouldn't automatically disqualify a patient, but the patient would still need to meet \*all\* the other inclusion criteria (breast cancer, specific surgery dates, etc.) and \*none\* of the exclusion criteria. Just having the EGFR mutation wouldn't make them eligible on its own.